PMID- 19010204
OWN - NLM
STAT- MEDLINE
DCOM- 20090623
LR  - 20220408
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 40
IP  - 9
DP  - 2008 Nov
TI  - Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the 
      prophylaxis of invasive fungal infections following lung transplantation.
PG  - 3090-3
LID - 10.1016/j.transproceed.2008.09.020 [doi]
AB  - BACKGROUND: Invasive fungal infections (IFIs) in patients undergoing lung 
      transplantation (LT) are associated with significant mortality. Previous studies 
      have shown the efficacy of aerosolized amphotericin B deoxycholate and oral 
      fluconazole for antifungal prophylaxis. Evolving data show a potential advantage 
      of prophylaxis with lipid-based formulations of amphotericin B in the prevention 
      of IFIs. We reviewed the incidence of IFIs among patients receiving aerosolized 
      amphotericin B lipid complex (ABLC) in LT. METHODS: We undertook a retrospective 
      review of the results of our antifungal protocol in a cohort of 60 LT patients. 
      We analyzed the efficiency, safety, and tolerability of 50 mg of aerosolized ABLC 
      administered postoperatively for IFI prophylaxis once every 2 days for 2 weeks 
      and then once per week for at least 13 weeks. In addition, these transplanted 
      patients received fluconazole (200 mg/d) during the first 21 days posttransplant. 
      The prophylaxis-related efficiency and safety were quantified for IFIs and 
      adverse events (AEs) for 6 months after study drug initiation. RESULTS: 
      Prophylaxis was efficient in 59 (98.3%) patients. Only one patient developed a 
      possible IFI, due to Aspergillus fumigatus. Four patients presented nausea and 
      vomiting as an AE, although aerosolized amphotericin B was ongoing. CONCLUSIONS: 
      Nebulized ABLC was effective, safe, and well tolerated for the prophylaxis of 
      aspergillosis in lung transplant patients during the early posttransplant period.
FAU - Borro, J M
AU  - Borro JM
AD  - Complejo Hospitalario Universitario Juan Canalejo, Servicio de Cirugia Toracica, 
      La Coruna, Spain. jmborro@canalejo.org
FAU - Sole, A
AU  - Sole A
FAU - de la Torre, M
AU  - de la Torre M
FAU - Pastor, A
AU  - Pastor A
FAU - Fernandez, R
AU  - Fernandez R
FAU - Saura, A
AU  - Saura A
FAU - Delgado, M
AU  - Delgado M
FAU - Monte, E
AU  - Monte E
FAU - Gonzalez, D
AU  - Gonzalez D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antifungal Agents)
RN  - 0 (liposomal amphotericin B)
RN  - 7XU7A7DROE (Amphotericin B)
RN  - 8VZV102JFY (Fluconazole)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Amphotericin B/administration & dosage/adverse effects/*therapeutic use
MH  - Antifungal Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aspergillosis/prevention & control
MH  - Child
MH  - Female
MH  - Fluconazole/administration & dosage/therapeutic use
MH  - Humans
MH  - Lung Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Mycoses/epidemiology/*prevention & control
MH  - Nausea/etiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Safety
MH  - Vomiting/etiology
MH  - Young Adult
EDAT- 2008/11/18 09:00
MHDA- 2009/06/24 09:00
CRDT- 2008/11/18 09:00
PHST- 2008/11/18 09:00 [pubmed]
PHST- 2009/06/24 09:00 [medline]
PHST- 2008/11/18 09:00 [entrez]
AID - S0041-1345(08)01279-7 [pii]
AID - 10.1016/j.transproceed.2008.09.020 [doi]
PST - ppublish
SO  - Transplant Proc. 2008 Nov;40(9):3090-3. doi: 10.1016/j.transproceed.2008.09.020.